Risk and potential risk reduction in diabetes type 2 patients in Germany

European Journal of Health Economics

Volumn 6, Issue 2, 2005, Pages 152-158

  Häussler, Bertram ^a   Berger, Ursula ^a   Mast, Oliver ^b   Thefeld, Wolfgang ^c  

^a Institut fur Sozialforschung   (Germany)

^b Hestia Health Care GmbH   (Germany)

^c ROBERT KOCH INSTITUTE   (Germany)

Author keywords

Diabetes mellitus type 2; Diabetes related complications; Prevalence rate; Risk; Risk reduction

Indexed keywords

CHOLESTEROL; HEMOGLOBIN A1C;

ARTICLE; BLOOD PRESSURE MEASUREMENT; BODY MASS; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DIABETIC NEPHROPATHY; DIABETIC RETINOPATHY; DISEASE DURATION; HEALTH SURVEY; HEART INFARCTION; HEMOGLOBIN DETERMINATION; HUMAN; MAJOR CLINICAL STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; PRACTICE GUIDELINE; PRIORITY JOURNAL; RISK ASSESSMENT; RISK REDUCTION; SAMPLE SIZE; SMOKING; STROKE;

ADULT; AGED; AGED, 80 AND OVER; DIABETES COMPLICATIONS; DIABETES MELLITUS, TYPE 2; FEMALE; GERMANY; HUMANS; INTERVIEWS AS TOPIC; MALE; MIDDLE AGED; QUALITY OF HEALTH CARE; RISK REDUCTION BEHAVIOR;

EID: 21344445081     PISSN: 16187598     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10198-004-0274-x     Document Type: Article

References (24)

1. Advisory Councel for the Concerted Action in Health Care (2001) Lessons from ten years of diabetes care in Germany. Appropriateness and efficiency, vol III. Bonn, pp 70-73
2. Bellach BM, Knopf H, Thefeld W (1998) Der Bundes-Gesundheitssurvey 1997/1998. Gesundheitswesen 60 [Suppl 2]:59-68
3. Brunetti P, Lucioni C, Schramm W (2002) Terapia combinata con pioglitazone (Actos) nel diabete di tipo2 in Italia: valutazione farmacoeconomica. In: Pharmacoeconomic issues in type 2 diabetes. vol 1, pp 26
4. Bundesärztekammer (2002) Nationale Versorgungsleitlinie Diabetes Mellitus Typ 2 Kurzfassung. Z Arztl Fortbild Qual Gesundh 96 [Suppl 2]:1-24
5. Gozzoli V, Palmer AJ, Brandt A, Weiss C, Piehlmeier W, Landgraf R, Renner R (2000) Increased clinical and economic advantages using PROSIT (proteinuria screening and intervention) in type 2 diabetic patients. Dtsch Med Wochenschr 125:1154-1159
6. Gozzoli V, Palmer AJ, Brandt A, Spinas GA (2001) Economic and clinical impact of alternative disease management strategies for secondary prevention in type 2 diabetes in the Swiss setting. Swiss Med Wkly 131-:303:310
7. Hauner H, Köster I, von Ferber L (2003) Ambulante Versorgung von Patienten mit Diabetes Mellitus im Jahr 2001. Dtsch Med Wochenschr 128:2638-2643
8. International Diabetes Federation (2003) Diabetes atlas, 2nd edn. International Diabetes Federation: Brussels
9. Knight EL, Kramer HM, Curhan CG (2003) High-normal blood pressure and microalbuminuria. Am J Kidney Dis 41:588-595
10. Kurth BM, Ellert U (2002) The SF-36 questionnaire and its usefulness in population studies: results of the German Health Interview and Examination Survey 1998. Sozpraventivmed 47:266-277
11. Liebl A, Mata M, Eschwege E; ODE-2 Advisory Board (2002) Evaluation of risk factors for development of complications in type II diabetes in Europe. Diabetologia 45:23-28
12. Neeser K, Lübben G, Siebert U, Schramm W (2004) Cost effectiveness of combination therapy with pioglitazone for type 2 diabetes mellitus from a German statutory healthcare perspective. Pharmacoeconomics 22:321-341
13. Mathers CD, Stein C, Ma Fat D, Rao C, Inoue M, Tomijima N, Bernard C, Lopez AD, Murray C (2002) Global burden of disease 2000: version 2 methods and results. Global programme on evidence for health policy discussion paper no 50. WHO: Geneva
14. Mooy JM, Grootenhuis PA, De Vries H, Valkenburg HA, Bouter LM, Kostense PJ, Heine RJ (1995) Prevalence and determinants of glucose intolerance in a Dutch caucasian population: the Hoorn study. Diabetes Care 18:1270-1273
15. Palmer AJ, Weiss C, Brandt A, Singh G, Wenzel H (1997) Cost-effectiveness of intensive therapy for type 1 diabetes changes depending on risk factors and level of existing complications. Medl Decis Making 17:528
16. Palmer AJ, Weiss C, Sendi PP, Neeser K, Brandt A, Singh G, Wenzel H, Spinas GA (2000) The cost-effectiveness of different management strategies for type I diabetes: a Swiss perspective. Diabetologia 43:13-26
17. Sharma AM, Wittchen HU, Kirch W, Pittrow D, Ritz E, Goke B, Lehnert H, Tschope D, Krause P, Hofler M, Pfister H, Bramlage P, Unger T, HYDRA Study Group (2004) High prevalence and poor control of hypertension in primary care: cross-sectional study. J Hypertens 22:479:486
18. Stiegler H, Standl E, Frank S, Mendler G (1998) Failure of reducing lower extremity amputations in diabetic patients: results of two subsequent population based surveys 1990 and 1995 in Germany. Vasa 27:10-14
19. Thefeld W, Stolzenberg H, Bellach BM (1999) Bundes-Gesundheitssurvey: Response, Zusammensetzung derTeilnehmer und Non-Responder-Analyse. Gesundheitswesen 61 [Suppl 2]:57-61
20. UKPDS Study group, Davies TME, Millns H, Stratton IM, Holman RR, Turner RC (1999) Risk factors for stroke in non-insulin dependent diabetes mellitus: UKPDS 29. Arch Intern Med 159:1097-1103
21. UKPDS Study group (1998) Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ 317:703-713
22. UKPDS Study group, Adler AI, Stevens RJ, Manley SE, Bilous RW, Cull CA, Holman RR (2003) Development and progression of nephropathy in type 2 diabetes: observation and modelling from the United Kingdom Prospective Diabetes Study (UKPDS 64). Kidney Int 63:225-232
23. Wolf PA, D'Agostino RB, Belanger AJ, Kannel WB (1991) Probability of stroke: a risk profile from the Framingham study. Stroke 22:312-318
24. World Health Organization (2002) World health report 2002. WHO: Geneva